Louis Manzo - Jan 3, 2023 Form 4 Insider Report for CAPRICOR THERAPEUTICS, INC. (CAPR)

Role
Director
Signature
/s/ Linda Marban, Attorney-in-Fact
Stock symbol
CAPR
Transactions as of
Jan 3, 2023
Transactions value $
$0
Form type
4
Date filed
1/5/2023, 07:01 PM
Previous filing
Apr 1, 2022
Next filing
Feb 23, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CAPR Stock Option (Right to Buy) Award $0 +37.8K $0.00 37.8K Jan 3, 2023 Common Stock 37.8K $3.85 Direct F1
transaction CAPR Stock Option (Right to Buy) Award $0 +7.12K $0.00 7.12K Jan 3, 2023 Common Stock 7.12K $3.85 Direct F2
transaction CAPR Stock Option (Right to Buy) Award $0 +19K $0.00 19K Jan 3, 2023 Common Stock 19K $3.85 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares vest 1/12th of the first day of each month, commencing February 1, 2023, with the last month vesting on December 31, 2023, until the stock option becomes fully vested and exercisable. The award pertains to annual board service. The option is subject to early exercise and, therefore, all or any part of the option can be exercised at any time. If the reporting person elects to take advantage of the early exercise feature and purchase shares prior to the vesting of such shares, the shares will be deemed restricted stock and will be subject to a repurchase option in favor of the Issuer if the reporting person's service to the Issuer terminates prior to vesting.
F2 The shares of the award are fully vested and exercisable as of January 3, 2023, the date of the grant. The award pertains to annual board committee service.
F3 The shares of the award are fully vested and exercisable as of January 3, 2023, the date of the grant. The award pertains to annual board service.